Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


We utilise our cutting-edge, exclusive workflow to develop focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9UL15

UPID:
BAG5_HUMAN

ALTERNATIVE NAMES:
Bcl-2-associated athanogene 5

ALTERNATIVE UPACC:
Q9UL15; O94950; Q86W59

BACKGROUND:
The protein BAG family molecular chaperone regulator 5, alternatively named Bcl-2-associated athanogene 5, is integral to the HSP70 chaperone system. It promotes ADP release from HSP70, activating protein refolding processes. Its role extends to proteostasis at junctional membrane complexes and inhibition of ubiquitination, underscoring its importance in cellular homeostasis and stress responses.

THERAPEUTIC SIGNIFICANCE:
The association of BAG family molecular chaperone regulator 5 with early-onset dilated cardiomyopathy (CMD2F) underscores its therapeutic potential. Targeting this protein's pathway could lead to innovative treatments for heart diseases, leveraging its critical role in protein folding and cellular stress management.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.